Lilly announced today that it plans to invest €2.3 billion ($2.5 billion) in the construction of a new high-tech manufacturing facility in Alzey, Germany. The company...
Eli Lilly announced that it is acquiring radiopharmaceutical company Point Biopharma for $12.50 per share in cash, valuing the deal at approximately $1.4 billion. Point...
Major drugmaker Eli Lilly has agreed to acquire Versanis Bio, a privately held obesity drug maker, for up to $1.925 billion. The transaction is subject to customary...
Major drugmaker Eli Lilly is to pay up to $2.4 billion to acquire Dice Therapeutics, a US biotech specializing in developing oral medicines to treat chronic autoimmune...
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin...
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing...
Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price...
